Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 646 to 660 of 734 results for diabet*

  1. Chief executive's end of year message

    Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.

    News
    Last updated
    8 December 2025

  2. NICE's prioritisation process explained – what healthtech developers need to know

    Understand why we're prioritising key topic areas for evaluation and what it means for innovators

    News
    Last updated
    4 December 2025

  3. Type 2 diabetes foot problems: Prevention and management of foot problems (CG10)

    This guidance has been updated and replaced by NICE guideline NG19.

    Clinical guideline
    Published
    28 January 2004

  4. Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Evidence summary
    Published
    13 October 2015

  5. Type 1 diabetes: insulin degludec (ESNM5)

    This evidence summary has been updated and replaced by NICE advice ESNM24.

    Evidence summary
    Published
    2 November 2012

  6. Type 2 diabetes: empagliflozin (ESNM35)

    This evidence summary has been replaced by NICE technology appraisal guidance 336.

    Evidence summary
    Published
    11 March 2014

  7. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Evidence summary
    Published
    2 November 2012

  8. Type 2 diabetes: The management of type 2 diabetes (CG87)

    This guidance has been updated and replaced by NICE guideline NG28.

    Clinical guideline
    Last updated
    1 December 2014

  9. Diabetes in pregnancy: Management of diabetes and its complications from pre-conception to the postnatal period (CG63)

    This guidance has been updated and replaced by NICE guideline NG3.

    Clinical guideline
    Published
    26 March 2008

  10. Type 2 diabetes (CG66)

    This guidance has been updated and replaced by NICE guideline NG28.

    Clinical guideline
    Published
    28 May 2008

  11. Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system) (DG21)

    This guidance has been updated and replaced by NICE technology appraisal guidance 943.

    Diagnostics guidance
    Published
    12 February 2016

  12. Diabetic foot problems: Inpatient management of diabetic foot problems (CG119)

    This guidance has been updated and replaced by NICE guideline NG19.

    Clinical guideline
    Published
    23 March 2011

  13. Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)

    This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.

    Clinical guideline
    Published
    23 July 2004

  14. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

    Evidence summary
    Published
    18 January 2013

  15. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    21 May 2013